Pliant Therapeutics: Good Data, But Will Need Watching [Seeking Alpha]
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: Seeking Alpha
Follow Summary Pliant Therapeutics' stock initially surged, but has since fallen due to mixed trial results and competitive pressures. Bexotegrast showed promising results in IPF and PSC trials, but dose-response inconsistencies and competition raise concerns. Despite positive data, the stock's decline suggests market skepticism, further exacerbated by Novartis ending a partnership. With a cash runway of 5-6 quarters, PLRX needs clarity on regulatory plans and later-stage trial data before making investment decisions. Vladimir Vladimirov I covered Pliant Therapeutics ( NASDAQ: PLRX ) in a negative article in December 2022. The stock more than doubled in a few weeks after my article. Today, however, the stock is down more than 30% from that time, so I will explore what happened. Background PLRX attempts to treat fibrosis by inhibiting integrin-mediated activation of TGF-ß. TGF-ß is a multifunctional cytokine involved in processes such as immune regulation, cell proli
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
News
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.MarketBeat
- PF Awareness Month emphasises the importance of early diagnosis [Yahoo! Finance]Yahoo! Finance
- Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024GlobeNewswire
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $33.00 price target on the stock.MarketBeat
PLRX
Earnings
- 11/9/23 - Beat
PLRX
Sec Filings
- 9/27/24 - Form 8-K
- 8/7/24 - Form 10-Q
- 8/7/24 - Form 8-K
- PLRX's page on the SEC website